4 per 100 py (95% confidence interval [CI]: 0.1, 2.7), with moderate heterogeneity (I2 = 62%, 95% CI: 0%, 87%) (Fig. 2). Incidence among detainees with a history of IDU ranged from 5.5 per 100 py to 34.2 per 100 py. The summary incidence

estimate was 16.4 per 100 py (95% CI: 0.8, 32.1), with moderate heterogeneity (I2 = 67%, 95% CI: 0%, 90%) (Fig. 2). There were 93 sources of data for anti-HCV prevalence among general detainee samples. The summary anti-HCV prevalence estimate among general population detainees was 26% (95% CI: 23%, 29%), with high heterogeneity (I2 = 100%, 95% CI: 100%, 100%) (Fig. 3). A subanalysis by geographical region revealed wide variations in prevalence. The lowest estimated regional prevalence was 3% (95% CI: 2%, 5%) in the Middle East and North Africa; however, learn more this was based on only one source.[27] The highest estimated regional prevalence was 38% (95% CI: 32%, 43%) in Central selleck inhibitor Asia; again, this was based on only one source (pers. commun., S. Karymbaeva, September 15 2012). The most important source of heterogeneity was the proportion of the sample with a history of IDU (meta-regression coefficient = 0.005, P < 0.0001, adjusted R2 = 49.23%) (Table 1); year of data collection was also a significant source of heterogeneity, with more recent

sources having lower anti-HCV prevalence (meta-regression coefficient = −0.009, P = 0.001, adjusted R2 = 12.57%). Prevalence was also lower in sources with data derived from

random samples compared to convenience samples (18% versus 28%, meta-regression coefficient 0.096, P = 0.042, adjusted R2 = 3.92%). Among general detainee data sources, 62 contributed data for male-only samples, with a summary prevalence estimate of 24% (95% CI: 21%, 27%; I2 = 99%,95% CI: 99%, 99%). There were 37 female-only samples, and estimated summary prevalence was 32% (95% CI: 26%, 38%; I2 = 98%, 95% CI: 98%, MCE公司 99%). Fifty-one sources contributed data on anti-HCV prevalence among detainees with a history of IDU. History of IDU was determined through self-report in 49 sources, and physician examination in two sources. The estimated summary anti-HCV prevalence was 64% (95% CI: 58%, 70%), with high heterogeneity I2 = 99%, 95% CI: 99%, 99%) (Fig. 4). Regional prevalence estimates ranged from 23% (95% CI: 16%, 31%) in Latin America to 73% (95% CI: 64%, 81%) in Western Europe. Prevalence was lower in more recent sources (meta-regression coefficient = −0.139, P = 0.007, R2 = 12.67%) (Table 1). The summary prevalence estimate in men with history of IDU (26 sources) was 67% (95% CI: 58%, 75%; I2 = 99%,95% CI: 99%, 99%); among women with a history of IDU (seven sources), it was 64% (95% CI: 52%, 77%; I2 = 94%, 95% CI: 90%, 96%). Only two eligible data sources reported anti-HCV prevalence in extrajudicial detention centers for people who use drugs. In Chu et al.